Development of a novel ophthalmic ciclosporin A-loaded nanosuspension using top-down media milling methods

Pharmazie

Volumn 66, Issue 7, 2011, Pages 491-495

  Kim, Jeong Hoon ^a   Jang, Sun Woo ^a   Han, Sang Dug ^a   Hwang, Hyung Don ^a   Choi, Han Gon ^b  

^a Dong A Pharmaceutical Company   (South Korea)

^b Hanyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; POLYMER; POLYSTYRENE; ZIRCONIUM OXIDE; CYCLOSPORIN; EYE DROPS; IMMUNOSUPPRESSIVE AGENT; IRRITANT AGENT; NANOPARTICLE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; EYE IRRITATION; MALE; NONHUMAN; PARTICLE SIZE; RABBIT; SCHIRMER TEST; SEDIMENTATION; SUSPENSION; ANIMAL; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CONJUNCTIVITIS; DRUG EFFECT; DRUG STABILITY; EYE; LACRIMAL FLUID; METHODOLOGY; PATHOLOGY; SOLUBILITY;

ANIMALS; CONJUNCTIVITIS; CYCLOSPORINE; DRUG COMPOUNDING; DRUG STABILITY; EYE; IMMUNOSUPPRESSIVE AGENTS; IRRITANTS; MALE; NANOPARTICLES; OPHTHALMIC SOLUTIONS; PARTICLE SIZE; POLYMERS; RABBITS; SOLUBILITY; SUSPENSIONS; TEARS;

EID: 80051936901     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2011.0358     Document Type: Article

References (18)

1. Basa S, Muniyappan T, Karatgi P, Prabhu R, Pillai R (2008) Production and in vitro characterization of solid dosage form incorporating drug nanoparticles. Drug Dev Ind Pharm 34: 1209-1218.
2. Cerdeira AM, Mazzotti M, Gander B (2010) Miconazole nanosuspensions: Influence of formulation variables on particle size reduction and physical stability. Int J Pharm 396: 210-218.
3. Jadhav KR, Shaikh IM, Ambade KW, Kadam VJ (2006) Applications of microemulsion based drug delivery system. Curr Drug Deliv 3: 267-273. (Pubitemid 44031625)
4. Kapoor Y, Chauhan A (2008) Ophthalmic delivery of cyclosporin A from Brij-97 microemulsion and surfactant-laden p-HEMA hydrogels. Int J Pharm 361: 222-229.
5. Kobierski S, Ofori-Kwakye K, Müller RH, Keck CM (2009) Resveratrol nanosuspensions for dermal application-production, characterization, and physical stability. Pharmazie 64: 741-747.
6. Lallemand F, Felt-Baeyens O, Besseghir K, Behar-Cohen F, Gurny R (2003) Cyclosporin A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm 56: 307-318. (Pubitemid 37346503)
7. Lallemand F, Furrer P, Felt-Baeyens O, Gex-Fabry M, Dumont JM, Besseghir K, Gurny R (2005) A novel water-soluble cyclosporin A prodrug: ocular tolerance and in vivo kinetics. Int J Pharm 295: 7-14. (Pubitemid 40558784)
8. Pardeike J, Müller RH (2010) Nanosuspensions: a promising formulation for the new phospholipase A2 inhibitor PX-18. Int J Pharm 391: 322-329.
9. Rx list (2010) Restasis side effects and drug interactions. http://www.rxlist.com/restasis-drug.htm. Jul. 9.
10. Said T, Dutot M, Martin C, Beaudeux JL, Boucher C, Enee E, Baudouin C, Warnet JM, Rat P (2007) Cytoprotective effect against UV-induced DNA damage and oxidative stress: role of new biological UV filter. Eur J Pharm Sci 30: 203-210. (Pubitemid 46282436)
11. Shen J, Wang Y, Ping Q, Xiao Y, Huang X (2009) Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery. J Control Release 137: 217-223.
12. Tang-Liu DD, Acheampong A (2005) Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye. Clin Pharmacokinet 44: 247-261. (Pubitemid 40477788)
13. Toshida H, Nguyen DH, Beuerman RW, Murakami A (2009) Neurologic evaluation of acute lacrimomimetic effect of cyclosporin in an experimental rabbit dry eye model. Invest. Ophthalmol Vis Sci 50: 2736-2741.
14. Van Eerdenbrugh B, Froyen L, Van Humbeeck J, Martens JA, Augustijns P, Van den Mooter G. (2008) Drying of crystalline drug nanosuspensions-the importance of surface hydrophobicity on dissolution behavior upon redispersion. Eur J Pharm Sci 35: 127-135.
15. Van Eerdenbrugh B, Stuyven B, Froyen L, Van Humbeeck J, Martens JA, Augustijns P, Van den Mooter G. (2009) Downscaling drug nanosuspension production: processing aspects and physicochemical characterization. AAPS PharmSciTech 10: 44-53.
16. Verma S, Gokhale R, Burgess DJ (2009a) A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions. Int J Pharm 380: 216-222.
17. Verma S, Lan Y, Gokhale R, Burgess DJ (2009b) Quality by design approach to understand the process of nanosuspension preparation. Int J Pharm 377: 185-198.
18. Woo JS, Piao MG, Li DX, Ryu DS, Choi JY, Kim JA, Kim JH, Jin SG, Kim DD, Lyoo WS, Yong CS, Choi HG (2007) Development of cyclosporin A-loaded hyaluronic microsphere with enhanced oral bioavailability. Int J Pharm 345: 134-141. (Pubitemid 350087552)